"Molecule ChEMBL ID";"Molecule Name";"Molecule Max Phase";"Molecular Weight";"#RO5 Violations";"AlogP";"Compound Key";"Smiles";"Standard Type";"Standard Relation";"Standard Value";"Standard Units";"pChEMBL Value";"Data Validity Comment";"Comment";"Uo Units";"Ligand Efficiency BEI";"Ligand Efficiency LE";"Ligand Efficiency LLE";"Ligand Efficiency SEI";"Potential Duplicate";"Assay ChEMBL ID";"Assay Description";"Assay Type";"BAO Format ID";"BAO Label";"Assay Organism";"Assay Tissue ChEMBL ID";"Assay Tissue Name";"Assay Cell Type";"Assay Subcellular Fraction";"Assay Parameters";"Assay Variant Accession";"Assay Variant Mutation";"Target ChEMBL ID";"Target Name";"Target Organism";"Target Type";"Document ChEMBL ID";"Source ID";"Source Description";"Document Journal";"Document Year";"Cell ChEMBL ID";"Properties";"Action Type";"Standard Text Value";"Value"
"CHEMBL5605366";"";"None";"425.92";"0";"3.27";"ASAP-0029888";"O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'='";"43867.0";"nM";"4.36";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.03 None | IC50 CI (lower) = 40.77 uM | IC50 CI (upper) = 47.2 uM | Maximum measured = 67.84 None | Maximum response = 100.0 % | Minimum measured = -1.636 None | R squared = 0.992 None";"";"";"43.867"
"CHEMBL5598605";"";"None";"305.34";"0";"3.20";"ASAP-0029713";"O=C(Nc1ccc2c(c1)CNC2)c1cccc(-c2cnco2)c1";"IC50";"'='";"23301.0";"nM";"4.63";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.529 None | IC50 CI (lower) = 22.63 uM | IC50 CI (upper) = 23.99 uM | Maximum measured = 97.13 None | Maximum response = 100.0 % | Minimum measured = -3.123 None | R squared = 0.998 None";"";"";"23.301"
"CHEMBL5605468";"";"None";"295.32";"0";"3.16";"ASAP-0029832";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)c2[nH]ccc2c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 2.434 None | Minimum measured = -3.672 None";"";"";"99.5"
"CHEMBL5598898";"";"None";"323.78";"0";"3.74";"ASAP-0029711";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2ccncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.163 None | Maximum measured = 25.74 None | Maximum response = 100.0 % | Minimum measured = -4.215 None | R squared = 0.8 None";"";"";"99.5"
"CHEMBL5598765";"";"None";"420.90";"0";"3.59";"ASAP-0029650";"Cn1cc(CCc2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)cn1";"IC50";"'='";"26411.0";"nM";"4.58";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.142 None | IC50 CI (lower) = 23.77 uM | IC50 CI (upper) = 29.34 uM | Maximum measured = 86.93 None | Maximum response = 100.0 % | Minimum measured = -4.37 None | R squared = 0.978 None";"";"";"26.411"
"CHEMBL5598658";"";"None";"355.87";"0";"3.72";"ASAP-0029621";"CNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 0.711 None | Minimum measured = -2.777 None";"";"";"99.5"
"CHEMBL5598786";"";"None";"296.30";"0";"2.56";"ASAP-0029497";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.208 None | Maximum measured = 44.89 None | Maximum response = 100.0 % | Minimum measured = -4.073 None | R squared = 0.978 None";"";"";"99.5"
"CHEMBL5605372";"";"None";"323.42";"0";"3.22";"ASAP-0031633";"NCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12";"IC50";"'='";"11790.0";"nM";"4.93";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.904 None | IC50 CI (lower) = 11.19 uM | IC50 CI (upper) = 12.42 uM | Maximum measured = 98.86 None | Maximum response = 100.0 % | Minimum measured = -1.843 None | R squared = 0.992 None";"";"";"11.79"
"CHEMBL5605103";"";"None";"386.43";"0";"4.53";"ASAP-0031310";"Cc1ccccc1-c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1";"IC50";"'='";"3243.0";"nM";"5.49";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.421 None | IC50 CI (lower) = 3.081 uM | IC50 CI (upper) = 3.414 uM | Maximum measured = 98.68 None | Maximum response = 100.0 % | Minimum measured = 0.07 None | R squared = 0.998 None";"";"";"3.243"
"CHEMBL5606112";"";"None";"337.45";"0";"3.26";"ASAP-0031277";"NCCc1csc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.551 None | Maximum measured = 38.59 None | Maximum response = 100.0 % | Minimum measured = -2.566 None | R squared = 0.981 None";"";"";"99.5"
"CHEMBL5604470";"";"None";"397.41";"0";"4.10";"ASAP-0031299";"N#Cc1ccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)cc1";"IC50";"'='";"1917.0";"nM";"5.72";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.141 None | IC50 CI (lower) = 1.855 uM | IC50 CI (upper) = 1.981 uM | Maximum measured = 97.86 None | Maximum response = 100.0 % | Minimum measured = -0.772 None | R squared = 0.998 None";"";"";"1.917"
"CHEMBL3919119";"";"None";"454.34";"None";"None";"ASAP-0015081";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O";"IC50";"'='";"793.0";"nM";"6.10";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.486 None | IC50 CI (lower) = 0.723 uM | IC50 CI (upper) = 0.869 uM | Maximum measured = 99.66 None | Maximum response = 100.0 % | Minimum measured = -0.879 None | R squared = 0.988 None";"";"";"0.793"
"CHEMBL5605540";"";"None";"452.94";"0";"4.45";"ASAP-0027609";"CNC(=O)[C@H](Nc1cccc(CN)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.243 None | Maximum measured = 43.81 None | Maximum response = 100.0 % | Minimum measured = -0.958 None | R squared = 0.996 None";"";"";"99.5"
"CHEMBL5606153";"";"None";"423.90";"1";"5.11";"ASAP-0021119";"Cc1ccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1CN";"IC50";"'='";"70702.0";"nM";"4.15";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.125 None | IC50 CI (lower) = 65.51 uM | IC50 CI (upper) = 76.3 uM | Maximum measured = 64.94 None | Maximum response = 100.0 % | Minimum measured = -2.177 None | R squared = 0.972 None";"";"";"70.702"
"CHEMBL5606202";"";"None";"344.46";"0";"4.73";"ASAP-0021052";"Cc1[nH]c2ccccc2c1CN1CCC(c2c[nH]c3ncccc23)CC1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = -0.255 None | Minimum measured = -1.844 None";"";"";"99.5"
"CHEMBL5606457";"";"None";"464.87";"0";"3.61";"ASAP-0023274";"O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)c1)OCc1ccccc1";"IC50";"'='";"13947.0";"nM";"4.86";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.319 None | IC50 CI (lower) = 13.56 uM | IC50 CI (upper) = 14.34 uM | Maximum measured = 99.06 None | Maximum response = 100.0 % | Minimum measured = -0.738 None | R squared = 0.998 None";"";"";"13.947"
"CHEMBL5605532";"";"None";"341.46";"1";"5.10";"ASAP-0016252";"c1cc(C2CCN(Cc3c[nH]c4ccccc34)CC2)c2ccncc2c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.297 None | Maximum measured = 0.847 None | Maximum response = 100.0 % | Minimum measured = -1.029 None | R squared = 0.099 None";"";"";"99.5"
"CHEMBL5605186";"";"None";"461.01";"1";"6.83";"ASAP-0027756";"O=C(Nc1cc(Cl)cc([C@H]2C[C@@H]2c2cccc(C3CCNCC3)c2)c1)OCc1ccccc1";"IC50";"'='";"5509.0";"nM";"5.26";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 6.383 None | IC50 CI (lower) = 4.57 uM | IC50 CI (upper) = 6.641 uM | Maximum measured = 99.89 None | Maximum response = 100.0 % | Minimum measured = -3.106 None | R squared = 0.999 None";"";"";"5.509"
"CHEMBL5606429";"";"None";"378.41";"0";"3.36";"ASAP-0031147";"O=C(Nc1cc2c(c(C3=CCOCC3)c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'='";"29924.0";"nM";"4.52";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.768 None | IC50 CI (lower) = 28.21 uM | IC50 CI (upper) = 31.74 uM | Maximum measured = 95.73 None | Maximum response = 100.0 % | Minimum measured = -0.554 None | R squared = 0.993 None";"";"";"29.924"
"CHEMBL5604988";"";"None";"399.52";"0";"4.88";"ASAP-0031461";"NCc1cccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)c1";"IC50";"'='";"43725.0";"nM";"4.36";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.756 None | IC50 CI (lower) = 42.12 uM | IC50 CI (upper) = 45.39 uM | Maximum measured = 94.9 None | Maximum response = 100.0 % | Minimum measured = -1.837 None | R squared = 0.995 None";"";"";"43.725"
"CHEMBL5599838";"";"None";"459.98";"1";"5.16";"ASAP-0031456";"CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"4384.0";"nM";"5.36";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.182 None | IC50 CI (lower) = 4.084 uM | IC50 CI (upper) = 4.707 uM | Maximum measured = 98.47 None | Maximum response = 100.0 % | Minimum measured = 1.495 None | R squared = 0.996 None";"";"";"4.384"
"CHEMBL5605310";"";"None";"399.52";"0";"4.88";"ASAP-0031492";"NCc1ccc(-c2csc3cc(C(=O)Nc4ccc5c(c4)CNC5)ccc23)cc1";"IC50";"'='";"53235.0";"nM";"4.27";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.037 None | IC50 CI (lower) = 51.25 uM | IC50 CI (upper) = 55.3 uM | Maximum measured = 77.58 None | Maximum response = 100.0 % | Minimum measured = -2.253 None | R squared = 0.995 None";"";"";"53.235"
"CHEMBL5605069";"";"None";"311.77";"0";"3.68";"ASAP-0030001";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cc[nH]c12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 3.184 None | Minimum measured = -3.052 None";"";"";"99.5"
"CHEMBL5598611";"";"None";"326.79";"0";"3.08";"ASAP-0029588";"Cn1cc2cc(Cl)cc(C(=O)Nc3ccc4c(c3)CNC4)c2n1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.587 None | Maximum measured = 44.04 None | Maximum response = 100.0 % | Minimum measured = -3.423 None | R squared = 0.91 None";"";"";"99.5"
"CHEMBL5605521";"";"None";"296.35";"0";"3.17";"ASAP-0030106";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2c1CCC2";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 0.135 None | Minimum measured = -2.142 None";"";"";"99.5"
"CHEMBL5598576";"";"None";"405.88";"0";"4.36";"ASAP-0029491";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.517 None | Maximum measured = 15.44 None | Maximum response = 100.0 % | Minimum measured = -6.437 None | R squared = 0.618 None";"";"";"99.5"
"CHEMBL5598685";"";"None";"323.83";"0";"4.50";"ASAP-0029597";"N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 1.195 None | Minimum measured = -7.842 None";"";"";"99.5"
"CHEMBL5605090";"";"None";"336.37";"0";"3.67";"ASAP-0030071";"C=CC[C@H]1NCc2cc(NC(=O)c3cc(F)cc4[nH]ncc34)ccc21";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.264 None | Maximum measured = 36.78 None | Maximum response = 100.0 % | Minimum measured = -0.398 None | R squared = 0.995 None";"";"";"99.5"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"1471.0";"nM";"5.83";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.277 None | IC50 CI (lower) = 1.425 uM | IC50 CI (upper) = 1.518 uM | Maximum measured = 99.76 None | Maximum response = 100.0 % | Minimum measured = 0.852 None | R squared = 0.999 None";"";"";"1.471"
"CHEMBL5604375";"";"None";"323.79";"0";"3.50";"ASAP-0028904";"N#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 5.984 None | Maximum measured = 6.391 None | Maximum response = 100.0 % | Minimum measured = -1.003 None | R squared = 0.688 None";"";"";"99.5"
"CHEMBL5605947";"";"None";"435.91";"0";"4.99";"ASAP-0027652";"O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CCNC3)c1)OCc1ccccc1";"IC50";"'='";"32118.0";"nM";"4.49";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.855 None | IC50 CI (lower) = 30.67 uM | IC50 CI (upper) = 33.64 uM | Maximum measured = 94.53 None | Maximum response = 100.0 % | Minimum measured = -3.727 None | R squared = 0.993 None";"";"";"32.118"
"CHEMBL3919119";"";"None";"454.34";"None";"None";"ASAP-0015081";"N=C(N)NCCC[C@H](NC(=O)[C@H](Cc1ccc(CN)cc1)NC(=O)c1ccccc1)B(O)O";"IC50";"'='";"503.0";"nM";"6.30";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.315 None | IC50 CI (lower) = 0.478 uM | IC50 CI (upper) = 0.529 uM | Maximum measured = 99.75 None | Maximum response = 100.0 % | Minimum measured = 4.212 None | R squared = 0.997 None";"";"";"0.503"
"CHEMBL5605251";"";"None";"493.41";"1";"5.97";"ASAP-0015849";"CC(C)CNC(=O)c1cc(Cl)ccc1NS(=O)(=O)c1ccc(Oc2ccccc2Cl)cc1";"IC50";"'='";"15022.0";"nM";"4.82";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.462 None | IC50 CI (lower) = 13.56 uM | IC50 CI (upper) = 16.65 uM | Maximum measured = 86.8 None | Maximum response = 100.0 % | Minimum measured = -0.546 None | R squared = 0.986 None";"";"";"15.022"
"CHEMBL5604414";"";"None";"464.91";"1";"5.53";"ASAP-0027767";"O=C(Nc1cc(Cl)cc(C(=O)Nc2cccc([C@H]3C[C@H]3C(=O)O)c2)c1)OCc1ccccc1";"IC50";"'='";"32847.0";"nM";"4.48";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.304 None | IC50 CI (lower) = 31.58 uM | IC50 CI (upper) = 34.16 uM | Maximum measured = 97.3 None | Maximum response = 100.0 % | Minimum measured = -0.987 None | R squared = 0.995 None";"";"";"32.847"
"CHEMBL5605497";"";"None";"463.97";"1";"5.94";"ASAP-0023377";"N[C@H]1CC[C@H](c2ccc(NC(=O)c3cc(Cl)cc(NC(=O)OCc4ccccc4)c3)cc2)C1";"IC50";"'='";"7637.0";"nM";"5.12";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.539 None | IC50 CI (lower) = 7.396 uM | IC50 CI (upper) = 7.886 uM | Maximum measured = 100.0 None | Maximum response = 100.0 % | Minimum measured = -2.982 None | R squared = 0.998 None";"";"";"7.637"
"CHEMBL5605691";"";"None";"312.42";"0";"2.75";"ASAP-0027597";"Cc1c(C(=O)Nc2cc(CCCN)ccn2)cc(C2CC2)n1C";"IC50";"'='";"39227.0";"nM";"4.41";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 5.604 None | IC50 CI (lower) = 36.96 uM | IC50 CI (upper) = 41.63 uM | Maximum measured = 97.75 None | Maximum response = 100.0 % | Minimum measured = -3.15 None | R squared = 0.99 None";"";"";"39.227"
"CHEMBL5598593";"";"None";"309.76";"0";"3.59";"ASAP-0027972";"Clc1ccc2[nH]cc(Cc3ccc(-c4nn[nH]n4)cc3)c2c1";"IC50";"'='";"99140.0";"nM";"4.00";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.154 None | IC50 CI (lower) = 94.69 uM | IC50 CI (upper) = 103.8 uM | Maximum measured = 51.01 None | Maximum response = 100.0 % | Minimum measured = -1.525 None | R squared = 0.987 None";"";"";"99.14"
"CHEMBL5598749";"";"None";"421.88";"0";"4.94";"ASAP-0020915";"O=C(Nc1cc(Cl)cc(C(=O)Nc2ccc3c(c2)CNC3)c1)OCc1ccccc1";"IC50";"'='";"91263.0";"nM";"4.04";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.459 None | IC50 CI (lower) = 86.58 uM | IC50 CI (upper) = 96.2 uM | Maximum measured = 54.44 None | Maximum response = 100.0 % | Minimum measured = -4.008 None | R squared = 0.979 None";"";"";"91.263"
"CHEMBL5598591";"";"None";"373.29";"0";"4.60";"ASAP-0029041";"CC(C)(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 2.195 None | Minimum measured = -7.988 None";"";"";"99.5"
"CHEMBL5598732";"";"None";"359.27";"0";"4.43";"ASAP-0029050";"CC(C)c1cc(Br)cc(C(=O)Nc2ccc3c(c2)CNC3)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 0.036 None | Minimum measured = -9.741 None";"";"";"99.5"
"CHEMBL5606384";"";"None";"411.90";"0";"2.76";"ASAP-0028903";"CNC(=O)[C@H](Nc1cc(CN)cc(-c2nn[nH]n2)c1)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.466 None | Maximum measured = 8.093 None | Maximum response = 100.0 % | Minimum measured = -1.862 None | R squared = 0.735 None";"";"";"99.5"
"CHEMBL5604326";"";"None";"333.39";"0";"3.15";"ASAP-0030062";"C=CC[C@H]1NCc2cc(NC(=O)c3cccc4c3CC(=O)N4)ccc21";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.127 None | Maximum measured = 6.082 None | Maximum response = 100.0 % | Minimum measured = -1.395 None | R squared = 0.736 None";"";"";"99.5"
"CHEMBL5606236";"";"None";"375.20";"0";"3.32";"ASAP-0030085";"O=C(Nc1cc2c(cc1Br)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.198 None | Maximum measured = 34.8 None | Maximum response = 100.0 % | Minimum measured = -2.419 None | R squared = 0.988 None";"";"";"99.5"
"CHEMBL5606266";"";"None";"277.33";"0";"3.02";"ASAP-0029756";"O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]ccc2c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.772 None | Maximum measured = 16.19 None | Maximum response = 100.0 % | Minimum measured = -1.586 None | R squared = 0.897 None";"";"";"99.5"
"CHEMBL5605985";"";"None";"416.48";"0";"2.84";"ASAP-0031120";"CC(C)(c1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(F)cc2[nH]1)S(C)(=O)=O";"IC50";"'='";"18004.0";"nM";"4.75";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.382 None | IC50 CI (lower) = 17.56 uM | IC50 CI (upper) = 18.46 uM | Maximum measured = 98.04 None | Maximum response = 100.0 % | Minimum measured = -1.968 None | R squared = 0.999 None";"";"";"18.004"
"CHEMBL5604989";"";"None";"390.39";"0";"4.36";"ASAP-0031443";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3cccc(F)c3)nc12";"IC50";"'='";"3733.0";"nM";"5.43";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.774 None | IC50 CI (lower) = 3.575 uM | IC50 CI (upper) = 3.898 uM | Maximum measured = 98.57 None | Maximum response = 100.0 % | Minimum measured = -0.703 None | R squared = 0.999 None";"";"";"3.733"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"1057.0";"nM";"5.98";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.223 None | IC50 CI (lower) = 1.015 uM | IC50 CI (upper) = 1.101 uM | Maximum measured = 99.78 None | Maximum response = 100.0 % | Minimum measured = 1.329 None | R squared = 0.999 None";"";"";"1.057"
"CHEMBL5598679";"";"None";"293.33";"0";"2.04";"ASAP-0029208";"O=C1Cc2c(cccc2C(=O)Nc2ccc3c(c2)CNC3)N1";"IC50";"'='";"15134.0";"nM";"4.82";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 5.653 None | IC50 CI (lower) = 14.59 uM | IC50 CI (upper) = 15.7 uM | Maximum measured = 98.8 None | Maximum response = 100.0 % | Minimum measured = -2.095 None | R squared = 0.998 None";"";"";"15.134"
"CHEMBL5598615";"";"None";"367.25";"0";"4.46";"ASAP-0029045";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2ccccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.935 None | Maximum measured = 43.15 None | Maximum response = 100.0 % | Minimum measured = -3.355 None | R squared = 0.955 None";"";"";"99.5"
"CHEMBL5605162";"";"None";"387.87";"0";"3.27";"ASAP-0028981";"CNC(=O)[C@H](Nc1cc(CN)cc(C(=O)O)c1)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 1.322 None | Minimum measured = -2.969 None";"";"";"99.5"
"CHEMBL5598631";"";"None";"312.80";"0";"3.68";"ASAP-0029051";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2c1CCC2";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 1.178 None | Minimum measured = -2.748 None";"";"";"99.5"
"CHEMBL5604667";"";"None";"422.49";"0";"4.20";"ASAP-0031355";"CC(C)c1nnc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)s1";"IC50";"'='";"9861.0";"nM";"5.01";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.406 None | IC50 CI (lower) = 9.48 uM | IC50 CI (upper) = 10.26 uM | Maximum measured = 94.83 None | Maximum response = 100.0 % | Minimum measured = 0.705 None | R squared = 0.995 None";"";"";"9.861"
"CHEMBL5604344";"";"None";"373.21";"0";"2.47";"ASAP-0029916";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(=O)[nH]c12";"IC50";"'='";"38670.0";"nM";"4.41";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.011 None | IC50 CI (lower) = 36.04 uM | IC50 CI (upper) = 41.49 uM | Maximum measured = 84.35 None | Maximum response = 100.0 % | Minimum measured = -2.628 None | R squared = 0.987 None";"";"";"38.67"
"CHEMBL5598575";"";"None";"399.92";"0";"3.74";"ASAP-0029415";"COCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 5.693 None | Minimum measured = -5.089 None";"";"";"99.5"
"CHEMBL5605142";"";"None";"474.95";"1";"6.00";"ASAP-0028883";"C=CC[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1";"IC50";"'='";"7778.0";"nM";"5.11";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.722 None | IC50 CI (lower) = 7.295 uM | IC50 CI (upper) = 8.293 uM | Maximum measured = 100.25 None | Maximum response = 100.0 % | Minimum measured = 0.082 None | R squared = 0.994 None";"";"";"7.778"
"CHEMBL5604328";"";"None";"459.90";"0";"4.95";"ASAP-0027741";"N#C[C@H](Nc1cccc(-c2nn[nH]n2)c1)c1cc(Cl)cc(NC(=O)OCc2ccccc2)c1";"IC50";"'='";"12446.0";"nM";"4.91";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.14 None | IC50 CI (lower) = 11.96 uM | IC50 CI (upper) = 12.95 uM | Maximum measured = 100.17 None | Maximum response = 100.0 % | Minimum measured = -0.253 None | R squared = 0.997 None";"";"";"12.446"
"CHEMBL5604332";"";"None";"312.76";"0";"3.07";"ASAP-0027808";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.798 None | Maximum measured = 28.23 None | Maximum response = 100.0 % | Minimum measured = -1.054 None | R squared = 0.973 None";"";"";"99.5"
"CHEMBL5605526";"";"None";"409.87";"0";"4.80";"ASAP-0016806";"NCc1cccc(NC(=O)c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1";"IC50";"'='";"34571.0";"nM";"4.46";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 5.611 None | IC50 CI (lower) = 33.24 uM | IC50 CI (upper) = 35.96 uM | Maximum measured = 96.02 None | Maximum response = 100.0 % | Minimum measured = -3.641 None | R squared = 0.996 None";"";"";"34.571"
"CHEMBL5598597";"";"None";"326.79";"0";"3.41";"ASAP-0029027";"CN1Cc2ccc(NC(=O)c3cc(Cl)cc4[nH]ncc34)cc2C1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.552 None | Maximum measured = 24.71 None | Maximum response = 100.0 % | Minimum measured = -2.071 None | R squared = 0.96 None";"";"";"99.5"
"CHEMBL5598717";"";"None";"565.08";"2";"6.65";"ASAP-0027928";"O=C(Nc1cc(Cl)cc([C@H]2CN(Cc3ccccc3)C[C@@H]2c2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1";"IC50";"'='";"6834.0";"nM";"5.17";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.429 None | IC50 CI (lower) = 6.402 uM | IC50 CI (upper) = 7.296 uM | Maximum measured = 98.68 None | Maximum response = 100.0 % | Minimum measured = -1.823 None | R squared = 0.995 None";"";"";"6.834"
"CHEMBL5604114";"";"None";"488.94";"0";"4.42";"ASAP-0027813";"O=C(Nc1cc(Cl)cc([C@H](C#CCO)Nc2cccc(-c3nn[nH]n3)c2)c1)OCc1ccccc1";"IC50";"'='";"15913.0";"nM";"4.80";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.657 None | IC50 CI (lower) = 15.18 uM | IC50 CI (upper) = 16.69 uM | Maximum measured = 98.28 None | Maximum response = 100.0 % | Minimum measured = -1.771 None | R squared = 0.996 None";"";"";"15.913"
"CHEMBL5604249";"";"None";"406.91";"1";"5.82";"ASAP-0022797";"NCc1cccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)c1";"IC50";"'='";"7937.0";"nM";"5.10";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.512 None | IC50 CI (lower) = 7.638 uM | IC50 CI (upper) = 8.247 uM | Maximum measured = 96.92 None | Maximum response = 100.0 % | Minimum measured = -1.82 None | R squared = 0.997 None";"";"";"7.937"
"CHEMBL5605184";"";"None";"311.32";"0";"2.18";"ASAP-0030065";"O=C1Cc2c(cc(F)cc2C(=O)Nc2ccc3c(c2)CNC3)N1";"IC50";"'='";"53673.0";"nM";"4.27";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.521 None | IC50 CI (lower) = 51.04 uM | IC50 CI (upper) = 56.45 uM | Maximum measured = 74.53 None | Maximum response = 100.0 % | Minimum measured = -1.249 None | R squared = 0.993 None";"";"";"53.673"
"CHEMBL5606160";"";"None";"372.40";"0";"4.22";"ASAP-0030089";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"5405.0";"nM";"5.27";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.509 None | IC50 CI (lower) = 4.845 uM | IC50 CI (upper) = 6.029 uM | Maximum measured = 94.88 None | Maximum response = 100.0 % | Minimum measured = -2.046 None | R squared = 0.992 None";"";"";"5.405"
"CHEMBL5605639";"";"None";"341.72";"0";"3.61";"ASAP-0029970";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C(F)(F)F)n1";"IC50";"'='";"22968.0";"nM";"4.64";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.727 None | IC50 CI (lower) = 22.32 uM | IC50 CI (upper) = 23.63 uM | Maximum measured = 98.65 None | Maximum response = 100.0 % | Minimum measured = -1.927 None | R squared = 0.998 None";"";"";"22.968"
"CHEMBL5605255";"";"None";"423.95";"0";"4.61";"ASAP-0030850";"C=CC[C@H]1NCc2cc(N[C@H](C(=O)NC(C)C)c3cc(Cl)cc4[nH]ncc34)ccc21";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.188 None | Maximum measured = 49.1 None | Maximum response = 100.0 % | Minimum measured = -1.606 None | R squared = 0.992 None";"";"";"99.5"
"CHEMBL5606319";"";"None";"426.47";"0";"2.76";"ASAP-0031155";"O=C(Nc1cc2c(c(C3=CCS(=O)(=O)CC3)c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'='";"49988.0";"nM";"4.30";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.161 None | IC50 CI (lower) = 48.18 uM | IC50 CI (upper) = 51.86 uM | Maximum measured = 68.67 None | Maximum response = 100.0 % | Minimum measured = -1.121 None | R squared = 0.997 None";"";"";"49.988"
"CHEMBL5604531";"";"None";"402.43";"0";"4.23";"ASAP-0031290";"COc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1";"IC50";"'='";"5321.0";"nM";"5.27";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.431 None | IC50 CI (lower) = 4.756 uM | IC50 CI (upper) = 5.953 uM | Maximum measured = 93.58 None | Maximum response = 100.0 % | Minimum measured = -0.347 None | R squared = 0.988 None";"";"";"5.321"
"CHEMBL5605561";"";"None";"333.40";"0";"2.11";"ASAP-0031692";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2c(C3CNC3)n[nH]c12";"IC50";"'='";"32175.0";"nM";"4.49";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.158 None | IC50 CI (lower) = 31.31 uM | IC50 CI (upper) = 33.06 uM | Maximum measured = 78.31 None | Maximum response = 100.0 % | Minimum measured = 0.462 None | R squared = 0.999 None";"";"";"32.175"
"CHEMBL5605274";"";"None";"390.39";"0";"4.36";"ASAP-0031221";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccccc3F)nc12";"IC50";"'='";"5232.0";"nM";"5.28";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.88 None | IC50 CI (lower) = 4.897 uM | IC50 CI (upper) = 5.589 uM | Maximum measured = 97.77 None | Maximum response = 100.0 % | Minimum measured = -2.216 None | R squared = 0.998 None";"";"";"5.232"
"CHEMBL5605908";"";"None";"403.42";"0";"3.63";"ASAP-0031141";"COc1cc(-c2cc(NC(=O)c3cc(F)cc4[nH]ncc34)cc3c2CNC3)ccn1";"IC50";"'='";"42482.0";"nM";"4.37";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.463 None | IC50 CI (lower) = 40.47 uM | IC50 CI (upper) = 44.6 uM | Maximum measured = 80.59 None | Maximum response = 100.0 % | Minimum measured = -1.416 None | R squared = 0.995 None";"";"";"42.482"
"CHEMBL5605238";"";"None";"375.50";"0";"4.13";"ASAP-0031464";"O=C(Nc1ccc2c(c1)CNC2)c1ccc2c(C3=CCNCC3)csc2c1";"IC50";"'='";"70031.0";"nM";"4.16";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.752 None | IC50 CI (lower) = 68.55 uM | IC50 CI (upper) = 71.54 uM | Maximum measured = 72.84 None | Maximum response = 100.0 % | Minimum measured = -0.878 None | R squared = 0.997 None";"";"";"70.031"
"CHEMBL5598577";"";"None";"326.79";"0";"3.11";"ASAP-0029079";"O=C(Nc1ccc2c(c1)CNCC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.944 None | Maximum measured = 11.15 None | Maximum response = 100.0 % | Minimum measured = -1.547 None | R squared = 0.874 None";"";"";"99.5"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"2575.0";"nM";"5.59";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.39 None | IC50 CI (lower) = 2.466 uM | IC50 CI (upper) = 2.69 uM | Maximum measured = 99.16 None | Maximum response = 100.0 % | Minimum measured = 0.426 None | R squared = 0.998 None";"";"";"2.575"
"CHEMBL5605549";"";"None";"294.31";"0";"1.71";"ASAP-0029783";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(=O)[nH]c12";"IC50";"'='";"74491.0";"nM";"4.13";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.327 None | IC50 CI (lower) = 72.71 uM | IC50 CI (upper) = 76.32 uM | Maximum measured = 72.75 None | Maximum response = 100.0 % | Minimum measured = -1.931 None | R squared = 0.995 None";"";"";"74.491"
"CHEMBL5598927";"";"None";"372.22";"0";"2.80";"ASAP-0029728";"O=C1Cc2c(cc(Br)cc2C(=O)Nc2ccc3c(c2)CNC3)N1";"IC50";"'='";"87949.0";"nM";"4.06";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.597 None | IC50 CI (lower) = 82.36 uM | IC50 CI (upper) = 93.91 uM | Maximum measured = 56.53 None | Maximum response = 100.0 % | Minimum measured = -1.347 None | R squared = 0.985 None";"";"";"87.949"
"CHEMBL5598743";"";"None";"425.96";"0";"4.27";"ASAP-0029555";"O=C(NC1CCOCC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.865 None | Maximum measured = 21.81 None | Maximum response = 100.0 % | Minimum measured = -1.078 None | R squared = 0.962 None";"";"";"99.5"
"CHEMBL5598746";"";"None";"435.96";"0";"4.02";"ASAP-0029471";"Cn1cc(CNC(=O)[C@H](Nc2ccc3c(c2)CNC3)c2cc(Cl)cc(C3CC3)c2)cn1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.082 None | Maximum measured = 8.206 None | Maximum response = 100.0 % | Minimum measured = -4.379 None | R squared = 0.566 None";"";"";"99.5"
"CHEMBL5598860";"";"None";"325.41";"0";"3.36";"ASAP-0029521";"Cc1c(C(=O)Nc2cc([C@H]3CCOC3)ccn2)cc(C2CC2)n1C";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 2.197 None | Minimum measured = -6.438 None";"";"";"99.5"
"CHEMBL5605183";"";"None";"389.38";"0";"2.84";"ASAP-0030767";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.071 None | Maximum measured = 44.69 None | Maximum response = 100.0 % | Minimum measured = -1.498 None | R squared = 0.993 None";"";"";"99.5"
"CHEMBL5598576";"";"None";"405.88";"0";"4.36";"ASAP-0030776";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.447 None | Maximum measured = 22.23 None | Maximum response = 100.0 % | Minimum measured = -1.083 None | R squared = 0.979 None";"";"";"99.5"
"CHEMBL5605716";"";"None";"305.34";"0";"2.80";"ASAP-0029967";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2nc(O)ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.855 None | Maximum measured = 1.914 None | Maximum response = 100.0 % | Minimum measured = -0.946 None | R squared = 0.263 None";"";"";"99.5"
"CHEMBL5604164";"";"None";"345.32";"0";"4.04";"ASAP-0030028";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2[nH]c(C(F)(F)F)cc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.515 None | Maximum measured = 13.65 None | Maximum response = 100.0 % | Minimum measured = -2.717 None | R squared = 0.883 None";"";"";"99.5"
"CHEMBL5598684";"";"None";"433.31";"0";"4.85";"ASAP-0029352";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"2956.0";"nM";"5.53";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.959 None | IC50 CI (lower) = 2.833 uM | IC50 CI (upper) = 3.084 uM | Maximum measured = 98.46 None | Maximum response = 100.0 % | Minimum measured = -1.591 None | R squared = 0.999 None";"";"";"2.956"
"CHEMBL5606033";"";"None";"293.33";"0";"2.04";"ASAP-0029950";"O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1";"IC50";"'='";"8206.0";"nM";"5.09";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 5.502 None | IC50 CI (lower) = 8.016 uM | IC50 CI (upper) = 8.4 uM | Maximum measured = 98.76 None | Maximum response = 100.0 % | Minimum measured = -1.337 None | R squared = 0.998 None";"";"";"8.206"
"CHEMBL5606232";"";"None";"278.31";"0";"2.42";"ASAP-0030093";"O=C(Nc1ccc2c(c1)CNC2)c1cccc2cn[nH]c12";"IC50";"'='";"44972.0";"nM";"4.35";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.377 None | IC50 CI (lower) = 43.95 uM | IC50 CI (upper) = 46.02 uM | Maximum measured = 91.67 None | Maximum response = 100.0 % | Minimum measured = -0.392 None | R squared = 0.998 None";"";"";"44.972"
"CHEMBL5605022";"";"None";"321.32";"0";"2.43";"ASAP-0031265";"N#Cc1cc2c(cc1NC(=O)c1cc(F)cc3[nH]ncc13)CNC2";"IC50";"'='";"36934.0";"nM";"4.43";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.114 None | IC50 CI (lower) = 35.42 uM | IC50 CI (upper) = 38.51 uM | Maximum measured = 74.76 None | Maximum response = 100.0 % | Minimum measured = -1.7 None | R squared = 0.997 None";"";"";"36.934"
"CHEMBL5604118";"";"None";"367.47";"0";"3.55";"ASAP-0031158";"NCCc1csc2cc(C(=O)Nc3cc([C@H]4CCOC4)ccn3)ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.637 None | Maximum measured = 3.362 None | Maximum response = 100.0 % | Minimum measured = -2.365 None | R squared = 0.238 None";"";"";"99.5"
"CHEMBL5604338";"";"None";"360.46";"0";"3.49";"ASAP-0031404";"O=C(Nc1ccc2c(c1)CNC2)c1ccc2[nH]cc(C3CCNCC3)c2c1";"IC50";"'='";"36746.0";"nM";"4.43";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 5.751 None | IC50 CI (lower) = 36.11 uM | IC50 CI (upper) = 37.39 uM | Maximum measured = 98.84 None | Maximum response = 100.0 % | Minimum measured = -0.757 None | R squared = 0.999 None";"";"";"36.746"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"1738.0";"nM";"5.76";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.3 None | IC50 CI (lower) = 1.688 uM | IC50 CI (upper) = 1.79 uM | Maximum measured = 99.46 None | Maximum response = 100.0 % | Minimum measured = 1.199 None | R squared = 0.999 None";"";"";"1.738"
"CHEMBL5605856";"";"None";"406.91";"1";"5.82";"ASAP-0027760";"NCc1ccc([C@H]2C[C@@H]2c2cc(Cl)cc(NC(=O)OCc3ccccc3)c2)cc1";"IC50";"'='";"6873.0";"nM";"5.16";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 5.223 None | IC50 CI (lower) = 6.644 uM | IC50 CI (upper) = 7.109 uM | Maximum measured = 99.43 None | Maximum response = 100.0 % | Minimum measured = -2.579 None | R squared = 0.998 None";"";"";"6.873"
"CHEMBL5604806";"";"None";"420.85";"1";"5.94";"ASAP-0027839";"O=C(Nc1cc(Cl)cc(-c2ccc3[nH]c(C(=O)O)cc3c2)c1)OCc1ccccc1";"IC50";"'='";"6916.0";"nM";"5.16";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.809 None | IC50 CI (lower) = 6.44 uM | IC50 CI (upper) = 7.426 uM | Maximum measured = 100.11 None | Maximum response = 100.0 % | Minimum measured = 0.071 None | R squared = 0.994 None";"";"";"6.916"
"CHEMBL5604180";"";"None";"312.76";"0";"3.07";"ASAP-0029911";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2cn[nH]c12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.118 None | Maximum measured = 27.94 None | Maximum response = 100.0 % | Minimum measured = -2.102 None | R squared = 0.95 None";"";"";"99.5"
"CHEMBL5604703";"";"None";"326.79";"0";"3.38";"ASAP-0029875";"Cc1nc2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Cl)cc2[nH]1";"IC50";"'='";"26724.0";"nM";"4.57";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.084 None | IC50 CI (lower) = 22.6 uM | IC50 CI (upper) = 31.6 uM | Maximum measured = 77.56 None | Maximum response = 100.0 % | Minimum measured = -1.647 None | R squared = 0.938 None";"";"";"26.724"
"CHEMBL5605533";"";"None";"418.88";"0";"4.75";"ASAP-0029841";"Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(Cl)cc3[nH]2)c1O";"IC50";"'='";"3539.0";"nM";"5.45";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 5.346 None | IC50 CI (lower) = 3.025 uM | IC50 CI (upper) = 4.142 uM | Maximum measured = 98.38 None | Maximum response = 100.0 % | Minimum measured = -4.631 None | R squared = 0.996 None";"";"";"3.539"
"CHEMBL5604418";"";"None";"351.88";"0";"4.95";"ASAP-0029785";"Clc1cc([C@@H]2C[C@H]2c2cccc(C3CCNCC3)c2)c2cn[nH]c2c1";"IC50";"'='";"5838.0";"nM";"5.23";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 14.44 None | IC50 CI (lower) = 0.0 uM | IC50 CI (upper) = 6405173075445682000 uM | Maximum measured = 100.1 None | Maximum response = 100.0 % | Minimum measured = -3.88 None | R squared = 0.998 None";"";"";"5.838"
"CHEMBL5605499";"";"None";"387.24";"0";"2.48";"ASAP-0029933";"Cn1c(=O)[nH]c2c(C(=O)Nc3ccc4c(c3)CNC4)cc(Br)cc21";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Maximum measured = 0.871 None | Minimum measured = -4.358 None";"";"";"99.5"
"CHEMBL5605115";"";"None";"375.20";"0";"3.32";"ASAP-0030792";"O=C(Nc1cc(Br)c2c(c1)CNC2)c1cc(F)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 0.899 None | Maximum measured = 39.87 None | Maximum response = 100.0 % | Minimum measured = -1.067 None | R squared = 0.946 None";"";"";"99.5"
"CHEMBL5598718";"";"None";"298.78";"0";"3.43";"ASAP-0029525";"Clc1cc(CNc2ccc3c(c2)CNC3)c2cn[nH]c2c1";"IC50";"'='";"38774.0";"nM";"4.41";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.282 None | IC50 CI (lower) = 36.44 uM | IC50 CI (upper) = 41.26 uM | Maximum measured = 91.74 None | Maximum response = 100.0 % | Minimum measured = -3.794 None | R squared = 0.994 None";"";"";"38.774"
"CHEMBL5605664";"";"None";"390.39";"0";"4.36";"ASAP-0031237";"O=C(Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]c(-c3ccc(F)cc3)nc12";"IC50";"'='";"3650.0";"nM";"5.44";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.03 None | IC50 CI (lower) = 3.44 uM | IC50 CI (upper) = 3.871 uM | Maximum measured = 98.09 None | Maximum response = 100.0 % | Minimum measured = -0.544 None | R squared = 0.998 None";"";"";"3.65"
"CHEMBL5605097";"";"None";"386.43";"0";"4.53";"ASAP-0031293";"Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1";"IC50";"'='";"5904.0";"nM";"5.23";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.752 None | IC50 CI (lower) = 5.172 uM | IC50 CI (upper) = 6.74 uM | Maximum measured = 94.51 None | Maximum response = 100.0 % | Minimum measured = -1.156 None | R squared = 0.987 None";"";"";"5.904"
"CHEMBL5599838";"";"None";"459.98";"1";"5.16";"ASAP-0030826";"CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]c(-c3ccccc3)nc12";"IC50";"'='";"14644.0";"nM";"4.83";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.146 None | IC50 CI (lower) = 14.19 uM | IC50 CI (upper) = 15.12 uM | Maximum measured = 92.08 None | Maximum response = 100.0 % | Minimum measured = 0.128 None | R squared = 0.999 None";"";"";"14.644"
"CHEMBL5598845";"";"None";"356.22";"0";"3.79";"ASAP-0029002";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Br)cc2[nH]ccc12";"IC50";"'='";"33752.0";"nM";"4.47";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.993 None | IC50 CI (lower) = 32.84 uM | IC50 CI (upper) = 34.69 uM | Maximum measured = 95.3 None | Maximum response = 100.0 % | Minimum measured = -0.593 None | R squared = 0.998 None";"";"";"33.752"
"CHEMBL5605520";"";"None";"352.82";"0";"2.97";"ASAP-0028990";"OCC#C[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'='";"22280.0";"nM";"4.65";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 6.313 None | IC50 CI (lower) = 21.34 uM | IC50 CI (upper) = 23.26 uM | Maximum measured = 98.07 None | Maximum response = 100.0 % | Minimum measured = -5.294 None | R squared = 0.996 None";"";"";"22.28"
"CHEMBL5604539";"";"None";"388.39";"0";"3.44";"ASAP-0030867";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(F)cc2[nH]ccc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.579 None | Maximum measured = 11.76 None | Maximum response = 100.0 % | Minimum measured = -1.333 None | R squared = 0.888 None";"";"";"99.5"
"CHEMBL5604695";"";"None";"352.83";"0";"4.19";"ASAP-0029944";"C=CC[C@H]1NCc2cc(NC(=O)c3cc(Cl)cc4[nH]ncc34)ccc21";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.423 None | Maximum measured = 15.73 None | Maximum response = 100.0 % | Minimum measured = -1.947 None | R squared = 0.903 None";"";"";"99.5"
"CHEMBL5605462";"";"None";"491.94";"0";"4.17";"ASAP-0027759";"CNC(=O)[C@H](Nc1cc(Cl)cc(NC(=O)OCc2ccccc2)c1)c1cccc(-c2nn[nH]n2)c1";"IC50";"'='";"61597.0";"nM";"4.21";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.254 None | IC50 CI (lower) = 58.66 uM | IC50 CI (upper) = 64.68 uM | Maximum measured = 85.02 None | Maximum response = 100.0 % | Minimum measured = -0.933 None | R squared = 0.987 None";"";"";"61.597"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"1859.0";"nM";"5.73";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.31 None | IC50 CI (lower) = 1.787 uM | IC50 CI (upper) = 1.933 uM | Maximum measured = 99.61 None | Maximum response = 100.0 % | Minimum measured = -0.459 None | R squared = 0.999 None";"";"";"1.859"
"CHEMBL5598576";"";"None";"405.88";"0";"4.36";"ASAP-0030775";"O=C(NCC(F)F)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.646 None | Maximum measured = 7.352 None | Maximum response = 100.0 % | Minimum measured = -2.055 None | R squared = 0.732 None";"";"";"99.5"
"CHEMBL5606201";"";"None";"389.85";"0";"3.93";"ASAP-0030082";"O=C(Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2nn(-c3ccccc3)nc12";"IC50";"'='";"5254.0";"nM";"5.28";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 4.557 None | IC50 CI (lower) = 4.987 uM | IC50 CI (upper) = 5.536 uM | Maximum measured = 98.51 None | Maximum response = 100.0 % | Minimum measured = -1.465 None | R squared = 0.999 None";"";"";"5.254"
"CHEMBL5606033";"";"None";"293.33";"0";"2.04";"ASAP-0029950";"O=C1Cc2cc(C(=O)Nc3ccc4c(c3)CNC4)ccc2N1";"IC50";"'='";"14015.0";"nM";"4.85";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 5.517 None | IC50 CI (lower) = 13.6 uM | IC50 CI (upper) = 14.44 uM | Maximum measured = 98.66 None | Maximum response = 100.0 % | Minimum measured = -2.425 None | R squared = 0.998 None";"";"";"14.015"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"2669.0";"nM";"5.57";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.408 None | IC50 CI (lower) = 2.512 uM | IC50 CI (upper) = 2.835 uM | Maximum measured = 99.4 None | Maximum response = 100.0 % | Minimum measured = -1.413 None | R squared = 0.997 None";"";"";"2.669"
"CHEMBL5605673";"";"None";"425.90";"0";"4.15";"ASAP-0027729";"CCc1cc(C(=O)Nc2cccc(-n3nn[nH]c3=O)c2)sc1-c1ccc(Cl)cc1";"IC50";"'='";"13062.0";"nM";"4.88";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 2.759 None | IC50 CI (lower) = 12.4 uM | IC50 CI (upper) = 13.76 uM | Maximum measured = 96.77 None | Maximum response = 100.0 % | Minimum measured = -0.095 None | R squared = 0.994 None";"";"";"13.062"
"CHEMBL5604849";"";"None";"409.96";"0";"4.89";"ASAP-0030790";"O=C(NCCC1CC1)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc(C2CC2)c1";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 12.06 None | Maximum measured = 12.85 None | Maximum response = 100.0 % | Minimum measured = -5.272 None | R squared = 0.629 None";"";"";"99.5"
"CHEMBL5598610";"";"None";"383.88";"0";"3.50";"ASAP-0029000";"CC(C)NC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'='";"49803.0";"nM";"4.30";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.666 None | IC50 CI (lower) = 47.49 uM | IC50 CI (upper) = 52.23 uM | Maximum measured = 78.66 None | Maximum response = 100.0 % | Minimum measured = -2.721 None | R squared = 0.994 None";"";"";"49.803"
"CHEMBL3740727";"";"None";"719.79";"2";"2.06";"ASAP-0000570";"N=C(N)NCCC[C@H](NC(=O)c1nccs1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(N)=O)c1ccc(OCc2ccc(C(F)(F)F)cc2)cc1";"IC50";"'='";"1143.0";"nM";"5.94";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.176 None | IC50 CI (lower) = 1.107 uM | IC50 CI (upper) = 1.18 uM | Maximum measured = 99.9 None | Maximum response = 100.0 % | Minimum measured = 0.372 None | R squared = 0.999 None";"";"";"1.143"
"CHEMBL5605910";"";"None";"413.91";"0";"3.13";"ASAP-0029914";"CCOCCNC(=O)[C@H](Nc1ccc2c(c1)CNC2)c1cc(Cl)cc2[nH]ncc12";"IC50";"'>'";"99500.0";"nM";"";"";"Falls Outside The Dose Series";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 1.065 None | Maximum measured = 20.24 None | Maximum response = 100.0 % | Minimum measured = -0.967 None | R squared = 0.971 None";"";"";"99.5"
"CHEMBL5604471";"";"None";"332.41";"0";"3.92";"ASAP-0029790";"Cc1c(C(=O)Nc2cc(-c3cccnc3)ccn2)cc(C2CC2)n1C";"IC50";"'='";"6829.0";"nM";"5.17";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 7.757 None | IC50 CI (lower) = 6.406 uM | IC50 CI (upper) = 7.278 uM | Maximum measured = 99.48 None | Maximum response = 100.0 % | Minimum measured = -1.66 None | R squared = 0.999 None";"";"";"6.829"
"CHEMBL5604216";"";"None";"397.41";"0";"4.10";"ASAP-0031247";"N#Cc1cccc(-c2nc3c(C(=O)Nc4ccc5c(c4)CNC5)cc(F)cc3[nH]2)c1";"IC50";"'='";"2861.0";"nM";"5.54";"";"";"UO_0000065";"";"";"";"";"0";"CHEMBL5604074";"Functional biochemical assay to identify treatments for viral infectious disease that targets Dengue virus type 4 NS2B-NS3 protease. Utilizing a direct enzyme activity measurement method, reading the fluorescence intensity is used to characterize the relative potency of inhibitors as IC50. Synthetic construct has been made based on Dengue virus type 4 (strain Philippines/H241/1956) by Centre for Medicines Discovery, University of Oxford, and the assay has been performed by Weizmann Institute of Science.The protocol is publicly available: dx.doi.org/10.17504/protocols.io.q26g7yebkgwz/v3";"F";"BAO_0000019";"assay format";"dengue virus type 4";"None";"None";"None";"None";"Construct protein sequence: SMADLSLEKAANVQWDEMADITGSSPIIEVKQDEDGSFSIRDIEETNMGGGGSGGGGSGALWDVPSPAAAQKATLTEGVYRIMQRGLFGKTQVGVGIHMEGVFHTMWHVTRGSVICHETGRLEPSWADVRNDMISYGGGWRLGDKWDKEEDVQVLAIEPGKNPKHVQTKPGLFKTLTGEIGAVTLDFKPGTSGSPIINRKGKVIGLYGNGVVTKSGDYVSAITQAERTGEPDYEVDEDEEFRK";"";"";"CHEMBL5705864";"NS3 protease";"dengue virus type 4";"SINGLE PROTEIN";"CHEMBL5604066";"71";"AI-driven Structure-enabled Antiviral Platform (ASAP)";"";"2024";"None";"Baseline response = 0.0 % | Hill slope = 3.195 None | IC50 CI (lower) = 2.681 uM | IC50 CI (upper) = 3.052 uM | Maximum measured = 96.34 None | Maximum response = 100.0 % | Minimum measured = -0.79 None | R squared = 0.996 None";"";"";"2.861"
